AMGN vs MRK · P/E 24, rev $10.05B vs P/E 33, rev $16.61B
Amgen Inc (AMGN) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the AMGN and MRK stock pages for the full models.
Not investment advice.